Navigation Links
Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
Date:11/5/2010

SEATTLE, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Credit Suisse 2010 Health Care Conference, Phoenix, AZ on November 11, 2010 at 1:30 p.m. ET.

The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is ... 2016 to 2023 and reach a figure of $6.34 ... a chronic disease and is affecting a huge population. ... This report is focused on emerging cancer diagnostics market ... propelled due to factors such as: increasing number of ...
(Date:3/28/2017)... 28, 2017  Medeon Biodesign, Inc., a ... pleased to announce that the Company led and ... Orthopedics, Inc., a San Jose, CA ... for orthopedic extremity applications.  The ... primarily due to procedure volume growth, lifestyle influences ...
(Date:3/28/2017)... 28, 2017  "US Cancer Generics Market Outlook ... indicators and trend analysis related to the emergence ... pharmaceutical market in US. The report analyzes various ... on cancer generics drugs in recent years. The ... billions of dollars for various stake holders involved ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage some ... Time Square, New York. , The program will be led by co- ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual American ... Diabetes Risk Test to find out if they are at risk for developing Type ... up the evening sky by programming the LAX pylons the color red. Downtown’s U.S. ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... ... on elected representatives in state legislatures and Congress to protect parental rights and ... public health and safety in America. , The demonstration coincides with a press ...
Breaking Medicine News(10 mins):